← Eichor
Study identifier: NCT02901184 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

Condition: Heart Failure With Preserved Ejection Fraction  ·  Sponsor: Uppsala University

PhasePhase 3
Planned participants2000
Who can joinAll sexes, 50 Years to 99 Years
Healthy volunteersNo

About this study

Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduces the composite of CV mortality and HF hospitalization as follows: Population: HFPEF patients in the Swedish Heart Failure Registry and HFPEF patients in US. HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N-terminal pro b-type Natriuretic Peptide) and EF\>=40%. Intervention and control: Randomized 1:1 to intervention: spironolactone + usual care vs. control: usual care alone. Outcome: Primary outcome cardiovascular death or time to HF hospitalization. Secondary outcomes include hospitalization for various causes, adverse events and treatment adherence. In Sweden outcomes are obtained automatically by linking with the Population, Patient and Drug Dispensed Registries. In the US, outcomes will be reported by sites and supplemented by data from a call center. The trial is event-driven with enrollment 7 years and study duration 9 years. For the primary outcome (CV Death or first HF hospitalization) with an event target of 721 events the sample size…

This description comes directly from the study's public registry record.

Talk to the study team

Anna Gustavsson (SWE)  ·  +46186110181  ·  anna.gustavsson@ucr.uu.se

Will Simmons (US)  ·  919-668-0541  ·  will.simmons@duke.edu

Always discuss trial participation with your own doctor first.

Locations (78)

Advanced Cardiovascular LLCAlexander City, Alabama, United StatesTerminated
University of Alabama at BirminghamBirmingham, Alabama, United StatesTerminated
Banner - University Medical GroupTucson, Arizona, United StatesTerminated
MedStar Cardiovascular Research NetworkWashington D.C., District of Columbia, United StatesTerminated
Howard University HospitalWashington D.C., District of Columbia, United StatesTerminated
Holy Cross HospitalFort Lauderdale, Florida, United StatesTerminated
Piedmont Atlanta HospitalAtlanta, Georgia, United StatesTerminated
Wellstar Health System, Inc.Marietta, Georgia, United StatesTerminated
Queens Medical CenterHonolulu, Hawaii, United StatesTerminated
Fox Valley Clinical Research Center, LLCAurora, Illinois, United StatesTerminated
University of Illinois at ChicagoChicago, Illinois, United StatesTerminated
Alexian Brothers Medical CenterElk Grove Village, Illinois, United StatesTerminated

+ 66 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02901184